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MMP-9A number of extensive reviews are available discussing the roles of MMPs in various aspects of cancer
progression from benign tumor formation to overt cancer present with deadly metastases. This review will
focus speciﬁcally on the evidence functionally linking the MMPs and tumor-induced angiogenesis in various
in vivomodels. Emphasis has been placed on the cellular origin of the MMPs in tumor tissue, the requirement
of proMMP activation and the resulting proteolytic activity for the induction and progression of tumor
angiogenesis, and the pleiotropic roles for some of the MMPs. The functional mechanisms of the angiogenic
MMPs are discussed as well as their catalytic detection in complex biological systems. In addition, the
contribution of active MMPs to metastatic spread and establishment of secondary metastasis will be
discussed in view of the ﬁndings indicating that MMPs are involved in the preparation of pre-metastatic
niches. Finally, the most recent evidence, indicating the pro-metastatic consequences of anti-angiogenic
therapies employing MMP inhibitors will be presented as examples highlighting possible outcomes of
interfering with the pleiotropic nature of the MMP functionality.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The growth and metastasis of solid tumors have been long
associated with the formation of new vasculature, i.e. tumor
neovascularization [1]. Neovascularization in malignant tissue occurs
mostly through the process of angiogenesis, i.e. formation of new
blood vessels from the pre-existing vascular network. Recently,
evidence has emerged that tumor neovascularization can also involve
vasculogenesis, a process of de novo formation of blood vessels from
endothelial cell progenitors. Both vasculogenesis and angiogenesis are
fundamental processes initiated at earliest stages of vertebrate animal
development [2], however angiogenesis is considered as the prevalent
process of new blood vessel formation in adult tissues [3].
Physiologic angiogenesis occurs during wound healing, during
estrogen cycles in female reproductive tract or in placenta during
pregnancy. Under these conditions, angiogenesis is strictly controlled
by complex regulators deﬁning the initiation and development of new
blood vessels and their subsequent involution. Pathological angio-
genesis is associated with numerous disease states, including
inﬂammation, vascular retinopathy, rheumatoid arthritis and cancer
[1,4–7]. The angiogenesis triggered in the benign solid tumor is a
critical process in the initiation of malignant stage of cancer and its
progression towards metastatic disease [1,8]. The establishment of+1 858 784 7333.
a).
ll rights reserved.new tumor blood vessels through vasculogenic process is associated
with the development of endothelial cell networks from the recruited
circulating endothelial cell progenitors [9,10]. In addition, vasculo-
genic mimicry is suggested to explain the mechanisms by which
tumor cells initiate gene expression and phenotypic characteristics of
endothelial cells [3,11,12].
Although pathological vascularization is frequently considered as a
dysregulated process of new blood vessel formation, it is tightly
regulated by a combination of interrelating factors similar to those
governing physiologic angiogenesis. In this regard, matrix metallo-
proteinases (MMPs) are among the major players implicated in both
malignant angiogenesis and vasculogenesis. From an initial recogni-
tion of a pro-angiogenic role for MMPs in angiogenesis, a full appre-
ciation of a deep complexity of MMP roles in new vessel formation has
accumulated in recent years. This complexity is underlined by a
discovery of several MMPs with clearly protective, anti-malignant
properties as well as a demonstration that individual MMPs can
exhibit pro- or anti-angiogenic properties depending on the type of
cancer or the stage of particular cancer development [13].
The family of mammalian MMPs comprises 24 endopeptidases
characterized by a multi-domain structure, a Zn-containing active site
and an overall requirement for activation of their zymogen forms
prior to exerting their enzymatic functions [14–16]. The MMPs are
represented by both secreted and membrane-tethered molecules,
enzymatic activity of which is ﬁnely balanced by the complex
interplay with their natural inhibitors, i.e. TIMPs (tissue inhibitors of
metalloproteinases) and availability of speciﬁc substrates. During
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cated in most physiological processes requiring tissue remodeling,
including formation of new blood vessels and re-organization of the
pre-existing vasculature.
2. The angiogenic switch: Induction of MMPs in the
premalignant tumor
Vascular networks in most healthy tissues are relatively stable
because of the quiescent state of adult endothelium. During tumor
growth, however, endothelial cells are induced to proliferate and
migrate and eventually, assemble in lumina-containing capillaries, i.e.
form new angiogenic blood vessels. Tumor angiogenesis invariably
results in the generation of distorted, irregular networks of tortuous,
dilatedbloodvessels [3,17]. Physiologically, tumor angiogenesis appears
to erupt at certain stage of tumor progression and therefore initiation of
tumor angiogenesis has been described as an angiogenic switch [1]. The
main mechanism underlying the angiogenic switch includes changing
the balance between the levels of activators and inhibitors of
angiogenesis in favor of activators [17]. Induction of tumor angiogenesis
is followed by stabilization of newly formed blood vessels and their
maturation, resulting ultimately with switching-off the process of neo-
vascularization. Amongnumerous strong regulators of tumor angiogen-
esis, MMPs have a special role as these proteolytic enzymes have been
ascribed with both pro-angiogenic and anti-angiogenic functions.
Under steady state physiologic conditions, the expression of MMPs
in most tissues is relatively low, with the possible exception of soluble
MMP-2, which appears to be expressed constitutively and is present in
plasmaat relatively high levels [18]. However, upon induction causedby
such conditions as hypoxia and inﬂammation, the levels of certain
MMPs are increased dramatically. Since the above-mentioned condi-
tions are associatedwith physiologic angiogenesis, positive correlations
have been suggested between MMPs and angiogenic switching in
cancer. The experimental proof that MMPs are required and necessary
for angiogenic induction came from transgenic mouse models and
rescue experiments in MMP-deﬁcient mice that directly linked MMP-9
and the appearance of new blood vessels in the developing tumor [17].
One of the ﬁrst experimental reports describing the angiogenic
switch was a study employing a multistage squamous epithelial
carcinogenesis model [19]. In this model, the initiation of angiogenesis
in the premalignant lesions was associated with the activation of
MMP-9 delivered by inﬂammatory mast cells. Although initiation of
angiogenesis was ablated in mast cell-deﬁcient mice, it did not
directly implicateMMP-9 in the angiogenic switch since in addition to
proMMP-9 mast cells release a variety of other potent proteases. Such
demonstration would require a speciﬁc ablation of MMP-9 in the
leukocytes inﬁltrating tumors at the avascular stage.
The conﬁrmation that MMP-9 triggers the angiogenic switch came
from a model of multistage pancreatic carcinogenesis in transgenic
RIP1-Tag2 mice [20]. In RIP1-Tag2 mice, MMP-2 and MMP-9 were
found upregulated during angiogenic switching occurring in the
hyperplastic islets. However, the genetic ablation of MMP-9, and not
MMP-2 deﬁciency, achieved in corresponding knockout mice was
associated with a coordinated lack of angiogenic induction. Of critical
importance was the demonstration that the transplantation of wild
type bonemarrow rescued the induction of angiogenesis in pancreatic
islets of MMP-9 null hosts, not only conﬁrming that MMP-9 triggers
the angiogenic switch, but that MMP-9 is delivered by bone marrow-
derived hematopoietic cells [20]. Since its ﬁrst introduction, theMMP-
9-mediated angiogenic switching mechanism during tumor progres-
sion has been demonstrated in a number of mouse models systems,
including models of ovarian cancer [21], cervical cancer [22,23],
colorectal cancer [24], neuroblastoma progression [25], pancreatic
cancer [26], glioblastoma development [27], mammary carcinoma
vascularization [28] and breast carcinoma metastasis [29]. Interest-
ingly, the effects ofMMP-9 ablation on tumor growthand angiogenesiscould depend on the genetic background of mice [29] or be not
manifested at all and require genetic ablation of an additional MMP,
e.g. MMP-2 [30].
The ﬁndings from the two above-mentioned independent models
employing single ablation of MMP-2, i.e. the pancreatic islet
carcinogenesis model [20] and malignant keratinocyte xenotrans-
plantation [30], have indicated that MMP-2 apparently does not
signiﬁcantly contribute to the angiogenic switch. The functional role
of MMP-2 and its proteolytic activity in angiogenic switching,
however, has been proposed in the in vivo model of chondrosarcoma
development, where suppression of tumor MMP-2 by speciﬁc
antisense oligonucleotides led to a substantial inhibition of chon-
drosarcoma nodule neovascularization [31]. Although illustrating that
MMP-2 could have contributed to tumor angiogenesis, this model did
not provide experimental conﬁrmation that MMP-2 was critically
required to initiate the switch from the avascular stage to angiogenic
phase. It is possible that the apparent discrepancy regarding the
putative role of MMP-2 in a switching to an angiogenic phenotype
could rely on the nature of the cancer model or the mode of MMP
delivery to the site of tumor angiogenesis, i.e. either by the host,
inﬂammatory leukocytes or tumor cells.
3. Cellular origin of MMPs in the angiogenic tumor
Tumor cells represent a powerful source of MMPs in the developing
tumor. Although initially tumor-derived MMPs were regarded as those
governing tumor metastasis and angiogenesis, accumulated evidence
has indicated that the roles of tumor-derived MMPs is much more
limited than ﬁrst thought and appear to be restricted mainly to tumor
cell migration and invasion [32,33]. Immunohistochemical and in situ
hybridization analyses in breast carcinoma patients did not indicate
MMP-9 expression in tumor cells, but conclusively associated MMP-9
with three different stromal cell types, i.e. neutrophils, macrophages
and vascular pericytes [34]. In the pancreatic carcinogenesis model,
immunohistochemistry revealed that MMP-9 was not expressed in
normal non-transgenic islets, nor in the carcinomaepithelial cells, but in
a small number of cells in close opposition to the developing vasculature
[20]. Importantly, MMP-9 was also identiﬁed in the basement
membrane and ECM, consistent with the localization of matrix-bound
VEGF released by this proteinase [20].
Increase in local concentration of MMPs in tumors undergoing an
angiogenic switch is closely associated with the inﬂammation driven
by pro-inﬂammatory cytokines and factors produced by tumor and/or
stromal cells. Among tumor-inﬁltrating leukocytes, the mononuclear
cells (monocytes and macrophages) and granulocytes (neutrophils,
eosinophils and basophils/mast cells) are considered to be the major
sources of MMPs [4,35] (Table 1). Reconstitution experiments with
MMP-9 null mice have demonstrated that MMP-9 produced by
inﬂammatory leukocytes derived from the donor bone marrow
signiﬁcantly contributes to tumor development and angiogenesis
[20–22,24,25].
Monocytes/macrophages are regarded as an obligatory cell type at
the site of tumor formation and angiogenesis [36–39]. Direct involve-
ment ofmacrophages in tumor progression andmetastasiswas demon-
strated by introducing a null mutation in the CSF1 gene, encoding the
macrophage colony-stimulating factor. In a mouse model of breast
cancer, the lack of mature macrophages in the CSF-1 null mutants was
associatedwith decreasedmammary tumor growth andmetastasis, but
substantial defects in tumor-induced angiogenesis were not reported
[40]. Later studies employing ablation of speciﬁc subsets of inﬁltrating
monocytes demonstrated that Tie2-positive proangiogenic monocytes
are required for tumor vessel formation [41]. Macrophages can produce
a broad cohort of MMPs with potent matrix-degrading capabilities,
including MMP-1, -2, -3, -7, -9, -10, -12, -13, -14, and -19 [42], among
which, MMP-9 has been proven to be directly involved in the induction
of tumor angiogenesis [22]. Recent evidence suggests that depending on
Table 1
Cellular origin of stromal MMPs implicated in tumor angiogenesis.
Cell Type Functional expression
of angiogenic MMP
References
Monocyte/
macrophages
MMP-9 [21,22,38,43,228]
MMP-13 [188]
Neutrophils MMP-9 [23,26,29,30,48,50,51,143,189]
Mast cells MMP-2 [229]
MMP-9 [19,52,230]
B lymphocytes MMP-9 [60]
T lymphocytes MMP-9 [54,57,59]
Tumor-associated
ﬁbroblasts
(mesenchymal cells)
MMP-1 [67]
MMP-7 [67]
MMP-9 [64]
MMP-14 [65,66]
MMP-19 [213]
Endothelial cells MMP-1 [68]
MMP-2 [231]
MMP-9 [232]
MMP-10 [68]
MMP-14 [16,28,68,69,71,72,231]
MMP-15 [68]
Perivascular cells
(pericytes/smooth
muscle cells)
MMP-9 [34]
MMP-14 [77,233]
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phages may express characteristically different spectra of MMPs and
their inhibitors [43]. In contrast to granulocytes poised to release their
MMPs on demand, macrophages, differentiating from extravasated
monocytes, require speciﬁc stimulation to up-regulate production of
theirMMPs. Interactionwith activated endothelial cells and adhesion to
ECM components appear to be major stimulators, which coordinately
upregulate MMPs in the recruited monocytes/macrophages.
The initial studies have implicated tumor-associatedmacrophages as
amajor cell type deliveringMMP-9 to the site of tumor progression and
angiogenic switch [22,36,37], however the precise lineage of inﬂam-
matory MMP-9-delivering cells in the tumors sometimes was not
determined [20,25,44]. On the other hand, evidence has accumulated
indicating the persistent presence of inﬁltrating granulocytes, especially
neutrophils in angiogenic tumors [4]. Histologically, inﬁltrating neu-
trophils and monocytes localize to the different areas in the angiogenic
tumors: neutrophils are predominantly found in the tumor interior,
whereas tumor-associated macrophages concentrate along the periph-
ery, demarcating the tumor/stroma border [26,45,46]. The MMPs
released by neutrophils include a neutrophil collagenase, MMP-8 and
a neutrophil gelatinase, MMP-9, shown to be a uniquely potent pro-
angiogenic enzyme [47,48]. Neutrophils, as opposed to other cell types,
are capableof immediate releaseof theirMMPcargoupon stimulation at
the inﬂammatory site [49,50], which appears to contribute to unique
functional potency of neutrophil MMP-9 in tumor growth and
angiogenesis. In several model systems, neutrophils were shown to be
the predominant source of MMP-9 in developing tumors [26,29,30,51].
Functional inhibition of macrophage inﬂux with an antibody against
monocyte-speciﬁc receptor CCR2 demonstrated that a compensatory
neutrophil response could be elicited and inﬁltrating neutrophils could
become an exclusive cellular source of angiogenic MMP-9 [23].
Mast cells, closely related to basophils, constitute another
leukocyte type present in angiogenic tumors and were shown to be
a major supplier of MMP-9 in squamous epithelial carcinomas [19].
Interestingly, the accumulation of mast cells in the angiogenic tissue,
e.g. in a limb ischemia model, was itself MMP-9-dependent and
impaired in MMP-9 null mice [52].Among hematopoietic cells of non-myeloid lineage, T and B lympho-
cytes are known to express an extensive number of MMPs, including
MMP-1, -2, -9, and -14 [53–58]. Up-regulation of MMP-9 in splenic T
lymphocytes via VEGF-mediated mechanisms was observed in mice
bearing mammary tumors [59]. It has been also supposed that the com-
binationofMMP-9 andVEGF secreted by leukemic B cells can augment an
angiogenic switch during disease progression [60]. However, functional
roles in tumor growth and angiogenesis for those MMPs that are derived
from tumor-associated lymphocytes remain mainly unexplored.
The induction of MMPs in the angiogenic tissue has been also
associated with increased production of MMPs by tumor- or cancer-
associated ﬁbroblasts. There is an increasing recognition of the
importance of tumor-associated ﬁbroblasts in cancer progression
and the mechanisms involving ﬁbroblast MMPs in the regulation of
tumor angiogenesis are actively investigated. Stromal ﬁbroblasts
exert their cancer-promoting properties by stimulating tumor growth
and angiogenesis, in part through elevated secretion of stromal cell-
derived factor 1, CXCL12 [61]. Recently, tumor-associated ﬁbroblasts
were shown to produce PDGF-2 serving as an angiogenic factor
conferring tumors with the ability to overcome anti-VEGF treatment
[62]. There is a complex tumor-stroma cross-talk [63], and tumor cells
can induce stromal ﬁbroblasts to express MMPs, including MMP-9
[64]. MMP-14 activity in ﬁbroblasts, regulated by one of the EMT
factors, i.e. Snail1, positively contributes to the induction of
angiogenesis [65,66]. Fibroblast-derived MMP-1 and MMP-7 over-
expressed in transgenic mice, have been linked with the increased
susceptibility to mammary cancer [67].
In the angiogenic tumor, the developing capillary network
presents a rich source of proangiogenic MMPs. With the exception
of MMP-2, endothelial cells are relatively deﬁcient in MMP expression
in quiescent state [18]. However, during sprouting and formation of
lumina-containing tubules, activated endothelial cells over-express
MMP-1, MMP-9 and -14 [15,16,68,69]. In the in vitro angiogenesis
models this de novo expression of MMPs is associated with matrix
proteolytic activity sensitive to natural and synthetic MMP inhibitors
[16,68,70]. A critical role for MMP-14 expression and its proteolytic
activity has been shown during neovessel formation in ex vivo and in
vivo models [71]. MMP-14 vascular expression in vivo is largely
conﬁned to the sprouting tip of neocappillary structures, where
endothelial cell proliferation and MMP-14-mediated collagen degra-
dation are coordinately localized [72]. In the complex environment of
primary tumors, in vivo expression of MMPs in the endothelial cells
appears to be under tight temporal regulation between the onset of
angiogenesis and completion of vascular maturation.
While newly forming capillary networkmatures, the vasculature is
stabilized by perivascular cells, enveloping the outer surface of
endothelial lumina-containing tubules and stabilizing primitive
endothelial cell network [73–75]. Pericytes and smooth muscle cells
are the most common perivascular cell types implicated in tumor
angiogenesis [6,76], and frequently smooth muscle cells expressing
smooth muscle actin (SMA) are referred to as pericytes. Expression of
MMP-9 in the vascular pericytes, but not in smooth muscle cells, was
described in primary tumors from breast cancer patients, suggesting a
putative role of MMP-9 produced by perivascular cells in ECM
remodeling and degradation during tumor angiogenesis [34]. The
experimental conﬁrmation that perivascular cells play a pivotal role in
tumor angiogenesis was obtained in the orthotopic metastasis model
of human neuroblastoma, where MMP-9-deﬁciency was associated
with signiﬁcantly reduced numbers of SMA-positive pericytes along
tumor microvessels, indicating the involvement of MMP-9 both in the
recruitment of pericytes to angiogenic vasculature and the functional
role of recruited pericytes in stabilization of vessel architecture [76].
An exclusive requirement for MMP-14 expression in vascular smooth
muscle cells was shown for their PDGF-dependent recruitment to the
sites of neovascularization in vivo [77]. There is also evidence that
vascular maturation is coordinated by endothelial cell/mural cell
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[72]. The interactions between pericytes and endothelial cells are
believed to result in the silencing of MMP activities upon maturation
of newly formed blood vessels [16], however the in vivo biochemical
mechanisms for inhibition of the enzymatic activity associated with
pericyte MMPs remain unclear.
The complex interplay at the level of multiple types of cells
delivering and producing multiple MMPs also includes another level
where different MMPs, their natural activators, inhibitors and
substrates, all interact with each other. This complexity, in turn,
would imply that the outcome of MMP functionality might vary from
setting to setting, depending on a particular tissue/cellular milieu in
either the normal or disease state.
4. In vivo activation of proMMPs during tumor angiogenesis
An increase in MMP expression is usually considered as a
contributing factor in the induction of malignant angiogenesis [20].
Nevertheless, it is the enzymatic activity of activated MMPs which
actually contributes to the outcome of their angiogenic functions.
Zymogen activation and enzymatic activity are regarded as the rate-
limiting factors in MMP functioning, including MMP-induced or MMP-
mediated angiogenesis [78]. However,most in vivo angiogenesismodels
are too complex to answer the question of howMMPs are activated and
at best only indicate how MMP zymogens could be activated [15].
To be activated, an MMP proenzyme should undergo the so called
cysteine switch, upon which a latent MMP gains its catalytic activity.
Themechanisms, attributed toMMPzymogen activation, involve direct
activation by another proteinase, reduction by oxidants or non-
physiologic reagents, and allosteric perturbation. All six membrane-
type MMPs (including MMP-14), a type II transmembrane MMP
(MMP-23) and two soluble MMPs (MMP-11 and -28) contain a furin-
cleavage motif and are activated intracellularly by one of the furin
proprotein convertases. Therefore, being detected on the cell surface or
in the ECM of angiogenic tissue, these MMPs could be considered as
“intrinsically” activated. However, the in vivo activation mechanisms
formost other, non-furin cleavedMMPs are largely unknown [15],with
the possible exception of MMP-2. The activation mechanism of the
secretory proMMP-2 by membrane-anchored MMP-14 in a complex
with TIMP-2 was demonstrated in a number of in vitro settings [79,80].
That such mechanism exists in vivo is correlatively supported by
independent observations showing decreased MMP-2 activation in
MMP-14nullmice [81] and the lack of efﬁcient proMMP-2 activation in
TIMP-2 knockoutmice [82], yet the functional importance of theMMP-
14/TIMP-2/MMP-2 axis in growth and development throughout life is
seriously debated [83].
There is evidence that plasmin and other serine proteinases such as
uPA are in vivo activators ofMMPs, although the data are often circums-
tantial and controversial [84]. Similarly, proMMP activation by oxidants
has been demonstrated in vitro, but the role of this mechanism has not
been established in the in vivo settings [15]. In view of the difﬁculties to
identify and conﬁrm in vivo activators of proMMPs, demonstrating the
activation status and/or activity of individual MMPs at the site of
angiogenesis appears to be an important, but severely underscored and
often ignored aspect of MMP angiogenic functionality.
5. Detection of MMP proteolytic activity in angiogenic tumors
Initial detection of MMPs in solid tumors in patients and mouse
modelswas focused on tumor cells. Elevated expressionofmanyMMPs,
usually at tumor/stroma border, was demonstrated by different
methods, including immunohistochemistry and in situ hybridization.
With the recognition of importance of tumor angiogenesis, more
detailed analyses have localized MMPs in close association with blood
vessels, and it becomes apparent that stromal cells, inﬂammatory cells
and perivascular cells express MMPs more frequently than tumor cells.Double staining for cell lineage-speciﬁc markers and select MMPs
allowed to demonstrate that recruited MMP-9-positive cells belonged
to the monocyte/macrophage lineage in ovarian carcinoma [21], while
MMP-9-positive cellswere representedbyneutrophils in themammary
gland, lung, and pancreatic islet tumors in transgenic mice [26,29].
Although quite informative, spatial localization of angiogenic MMPs,
detected by immunohistochemistry or in situ hybridization, does not
provide any information with regard to their activation status or actual
activity. In order to determine activation status of MMPs in angiogenic
tumors, tissue extractshavebeensubjected toSDS-PAGEwesternblot and
gelatin zymography analyses to determine relative levels of the pro-
enzymeand theactivated speciesof lowermolecularweight. In themouse
cancer progression models, gelatin zymography was employed to assess
and conﬁrm upregulation and activation of proMMP-2 and proMMP-9
during angiogenic switching in squamous epithelial carcinoma [19],
pancreatic islet carcinoma [20], chondrosarcoma nodules [31], and
cervical carcinoma [22,23]. Substrate gel proteolysis also can provide
insight as to the origin of MMPs in tumors. Thus, gelatin zymography
performed on neuroblastoma tumors indicated that MMP-9 originated
form the host cells since the transplanted tumor cells were MMP-9
deﬁcient [76]. Formally, substrate zymography of complex tissues,
especially xenografts, should be accompanied by western blotting to
conﬁrm the MMP and species speciﬁcities of corresponding gelatinolytic
bands, but suchconﬁrmatoryanalyses areperformedrather rarely [31,85].
The measurement of MMP activity in complex tissues, however, is
challenging [86]. Examples of direct and indirectmethods employed for
revealing MMP activity in live cells and unﬁxed tissues are listed in
Table 2. An in vitro angiogenesis starburstmodel, involving the addition
of enzymatically active MMPs with and without MMP inhibitors,
allowed further discrimination between the activities of two gelatinases
and conﬁrmed that the activity of MMP-9 was responsible for
endothelial cell sprouting and VEGF release in the pancreatic cancer
model [20]. The functional link between activation and activity ofMMP-
9 and the levels of released VEGF was also demonstrated in ovarian
carcinomamodel where activation of gelatinases was shown by gelatin
zymography and the requirement for the gelatinases' activity was
conﬁrmed with synthetic MMP inhibitors [87].
In situ gelatin zymography using two different approaches described
in Table 2, provides the advantage of detectingwithin the tissue sections
only proteolytically active MMPs [88–91]. However, resolution of these
methods is relatively low and does not allow for unambiguous
identiﬁcation of the speciﬁc cell types exhibiting gelatinolytic activity.
An elegant way to show functional activity of MMP in the tissues is
the use of mAbs or polypeptides speciﬁcally recognizing cryptic sites
exposed by MMP-mediated proteolysis in collagen I and IV and
laminin-containing ECM substrates [92–95]. A functional conﬁrma-
tion of the activation requirement for individual MMPs is offered by
MMP-speciﬁc function-blocking mAbs speciﬁcally inhibiting activa-
tion of proMMP-9 in both in vitro and in vivo settings [48,96,97].
A signiﬁcant amount of effort was placed on a direct visualization
of MMP activity in 3-dimensional in vitro and in vivo settings. The
ﬂuorescent probes for whole-cell protease activity and self-quenched
probes for protease cleavage have been used to determine the location
of proteolysis in migrating and invading tumor cells [91,98]. Three-
dimensional in vitro model systems employing multimodal micro-
scopic technologies gained a detailed knowledge about surface
localization of proteolytic activity of MMP-14 during tumor cell
migration and invasion [99,100]. Using analyses based on a DQ-
collagen probe and antibody detection of cleaved collagen, MMP-14,
overexpressed in tumor cells, was localized at two zones, i.e. the
leading tip of the cell, allowing for directional migration, and also
further back on the cell, allowing for the generation of a pulling force
to protrude forward [100]. A newly designed method allowing for
high spatial and temporal resolution of MMP-mediated proteolysis is
based on the use of a novel ﬂuorogenic collagen substrate serving as a
speciﬁc reporter of cell-associated protease activities [101]. By using
Table 2
Direct and indirect methods to measure MMP activity in live cells and unﬁxed tissues.
Direct methods Description
In situ gelatin (substrate) zymography Cell preparations or sections of unﬁxed tissues are brought into contact with a photographic emulsion containing gelatin or a
layer of ﬂuorescence-labeled gelatin or other substrates. After incubation, areas of enzymatic activity are revealed aswhite spots
in a dark background or as black spots in a ﬂuorescent background employing light or confocal ﬂuorescentmicroscopy [88-90].
In situ zymography using DQ-gelatin or other
ﬂuorescence-quenched substrates
The method is based on use of dye-quenched (DQ) gelatin. DQ-gelatin is heavily labeled with FITC molecules so that its
ﬂuorescence is quenched. Cleavage of DQ-gelatin by active gelatinases produces ﬂuorescent peptides that are visible
against a weakly ﬂuorescent background. The in situ zymography can be combined with simultaneous
immunohistochemical detection of a speciﬁc MMP in the same section [90,91].
Near-infrared optical imaging employing
MMP-sensitive probes
An optical imaging method designed to determine the activity of MMPs with speciﬁc MMP-sensitive probes by measuring
near-infrared ﬂuorescent signal intensity in live animals [234].
Time-resolved, multimodal microscopy using
confocal reﬂection and SHG
MMP activity is visualized by the use of speciﬁc probes for detecting cleavage of interstitial collagens by live cells, for
example the antibodies detecting the 3/4-1/4 cleavage epitope in type I collagen [235], while imaging native collagen
ﬁbers using confocal reﬂection or second harmonic generation (SHG) microscopy [100,236].
Detection of whole-cell protease activity
in live cells
Engineered fusion proteins with altered protease cleavage speciﬁcity are used to detect speciﬁc cell-surface proteolytic
activity. In conjunction with ﬂuorescence microscopy, the assay is used to speciﬁcally image the activity of cell-surface
proteases and metalloproteinases in live cells [98].
Detection of MMP activity in live cells by FRET Visualization of MMP activity is based on the detection of ﬂuorescence resonance energy transfer (FRET) induced by a
cleavage of MMP-speciﬁc substrate in the biosensor [237,238].
Imaging of MMP-mediated cleavage with
ﬂuorogenic biosensor probes
Fluorescence is generated by MMP-mediated cleavage of speciﬁc sites introduced into interstitial collagen. In combination
with high-resolution imaging, the ﬂuorescent biosensor serves as a reporter of protease activity on the surface of cells
migrating on 2-D or though 3-D collagen matrices [101].
Indirect methods Description
Starburst assay Endothelial cells are incorporated into collagen gels with or without individual MMPs and/or MMP inhibitors. In the
presence of a localized source of pro-angiogenic factors, such as an angiogenic tumor, endothelial cells converge in aMMP-
dependent manner to the source, forming tubes in a starburst pattern [239].
Detection of cryptic epitopes in ECM substrates Proteolytic cleavage of substrates such as collagen type IV can expose cryptic sites which are normally hidden within its
triple helical structure. These novel protease-exposed cryptic epitopes can be detected by immunohistochemistry with
speciﬁc monoclonal antibodies [92,112].
Immunodetection of activated MMPs Several monoclonal antibodies have been described as raised against activated forms of MMPs. However, the ability of any
of these mAbs to differentially recognize only activated enzymes has not been demonstrated deﬁnitively. Nevertheless,
detection of an activated MMP would not directly prove its functional proteolytic activity in the tissue.
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peptide site by MMP-2, -9, and -14, it has been demonstrated that the
protease activity of MMP-14 in migrating tumor cells is localized only
at the polarized leading edge [101]. The level of resolution offered by
this novel probe appears to allow for further detection ofMMP activity
in the in vivo settings, including tumor angiogenesis.
An interesting experimental setting to study the role of MMPs in
tumor cell invasion involves an addition of select reagents that results in
a complete inhibition of protease activity. In the presence of a broad
proteolytic inhibitor cocktail, tumor cells were shown both in vitro and,
importantly, in vivo, to change their migration from a mesenchymal,
protease-dependent mode to an amoeboid, non-proteolytic pattern.
This compensatory type ofmigrationwas associatedwith the formation
of a so called constriction ring allowing the cells to squeeze through the
collagenous ﬁbers [99,102]. An alternative point of view challenges the
amoeboidmechanism of tumor cell migration in in vitro assays and also
in some in vivo settings. According to this viewpoint, the activity of
MMP-14, and only MMP-14, is an absolute requirement for transgres-
sing physiologically relevant matrix barriers by tumor and endothelial
cells [103]. This notion is further supported by in vitro data demonstrat-
ing that a proteolysis-independent pattern of cell invasion is observed
only in artiﬁcially reconstituted collagen, which forms relatively porous
and non-cross-linked ﬁbrillar matrices [101,103].
The controversy in the above described experimental ﬁndings
illustrates the urgent need for novel sophisticated approaches to dissect
the in vivo matrix remodeling associated with the speciﬁc proteolytic
activity of individualMMPs. Recent advances in proteomic technologies,
including ABPP [104], PROTOMAP [105] and iTRAQ [106], will lead to
identiﬁcation on a global scale of distinct proenzyme activation eventsand speciﬁc substrate cleavage reactions that occur in complex
biological systems. Application of these technologies, employing
MMP-speciﬁc probes and inhibitors to the analysis of matching tissues
that are undergoing or not undergoing angiogenic switching, will allow
to determine which proMMPs become activated and which identiﬁable
substrates are cleaved coordinately with the induction of angiogenesis.
6. MMP-mediated proteolysis in tumor angiogenesis
The notion that MMPs play a critical role in tumor angiogenesis
comes from the initial appreciation of the potent matrix remodeling
abilities of this class of proteases linked to the tissue remodeling
necessary for angiogenesis [13,107–109].
6.1. MMP-mediated modiﬁcations of the angiogenic ECM
New vessel formation involves disassembling of the endothelial cell
layer and its anchoring basement membrane, migration and prolifera-
tion of individual endothelial cells, followed by their subsequent re-
assembling into lumina-containing blood vessels. Thus, being a spatial
process, angiogenesis obviously requires disruption of physical barriers
imposed by the dense extracellular matrix (ECM). Therefore, the
capacity of MMPs to proteolytically target and modify many complex
ﬁbrillar proteins has long implicated MMPs in ECM modiﬁcations
facilitating physiologic and tumor angiogenesis.
6.1.1. Generation of cryptic sites in the ECM
In addition to peptide bond cleavages of ECM molecules, MMP-
mediated proteolytic remodeling also includes an exposing of cryptic
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IV results in the exposure of several cryptic sites hidden within the
triple helical structure. These unmasked epitopes are recognized by
speciﬁc mAbs raised by a subtractive immunization technique
[111,112]. The HUIV26 cryptic epitope is exposed within the ECM of
angiogenic but not quiescent blood vessels. In some in vivo animal
model systems, interactions with this epitope was shown to regulate
the development of angiogenic blood vessels through the ligation of
αvβ3 integrin expressed de novo in the endothelial cells [92].
Detection of the HUIV26 cryptic site during retinal neovascularization
was prevented in MMP-9-deﬁcient, but not MMP-2-deﬁcient mice,
thereby implicating the proteolytic activity of MMP-9 in unmasking
this epitope in vivo [93]. Another cryptic epitope, recognized by mAb
HU177, could be exposed within three-dimensional collagen gels
following proteolysis by tumor and vascular smooth muscle cells. The
HU177 cryptic epitope is present in both interstitial collagen I and
basement membrane collagen IV and is selectively expressed in the
ECM of developing tumors and angiogenic vasculature in the chick
embryo CAM model [94].
As was predicted in Ref. [92], a systematic search for cryptic sites
resulted in identiﬁcation of novel cryptic epitopes unmasked by
MMPs in collagen IV and other ECM molecules, including collagen
VIII, XV, and XVIII [110]. It has been also shown that MMP-2 and
MMP-14 were capable of unmasking cryptic epitopes in laminin-5 in
vitro, however the physiological relevance of these epitopes in vivo
remained controversial [113]. In contrast, a potent peptide antago-
nist of a laminin-1 sequence has been shown to block angiogenesis
and tumor growth of breast carcinomas in the chick embryo assay
[114]. Evidence has also been provided for another cryptic epitope
within denatured and proteolyzed laminin-1, that is speciﬁcally
recognized by a synthetic peptide STQ selected by phage display [95].
Blocking of this epitope with the STQ peptide inhibited in vivo
angiogenesis in the CAM model, growth of s.c. melanoma xenografts
in immunodeﬁcient mice, and experimental metastasis in the chick
embryo [95]. These inhibitory effects of laminin peptide antagonists
indicate that during tumor angiogenesis laminin is proteolytically
modiﬁed, possibly by select MMPs, presenting “pro-angiogenic”
cryptic epitopes, which in turn regulate behavior of endothelial and
tumor cells.
6.1.2. Directional proteolysis of ECM by endothelial and tumor MMP-14
Among all MMPs, MMP-14 is one of the most potent modiﬁers of
the pericellular microenvironment [115]. MMP-14 has been ascribed
with exceptional capability in the execution of directional matrix
proteolysis, thereby governing migration and invasion of tumor and
endothelial cells within proteolytically modiﬁed ECM [65,101,116]. A
direct role for MMP-14 expressed on endothelial cells has been shown
for endothelial tubular formation in 2- and 3-dimensional matrices in
vitro [16,117,118], suggesting a functional role of MMP-14 in
endothelial cell assembly in vivo. The ﬁndings generated in a number
of in vitro, ex vivo and in vivo model systems have clearly implicated
MMP-14 in matrix modiﬁcations that allow for coordinated migration
and invasion of tumor and endothelial cells [71,100,101,103,119].
Moreover, there is strong evidence supporting the notion that MMP-
14 orchestrates such coordinated interplay during in vivo angiogenesis
induced in growing tumors [16,83,115,117,120].
6.1.3. Basement membrane remodeling by MMPs during angiogenesis
Basement membrane matrix, enriched in laminins and collagen IV,
provides support for both endothelial cells and perivascular cells.
During angiogenesis this basement membrane is proteolytically
reorganized: ﬁrst degraded at the onset of angiogenesis and then
re-assembled during maturation and stabilization [121,122]. MMP-
mediated degradation of basement membrane remodeling in turn
leads to either release of pro-angiogenic factors, unmasking cryptic
sites or generation of angiogenesis inhibitors [121]. Preferentialbasement membrane substrates for most MMPs were established in
vitro. In the in vivo setting, the activity of MMP-2, -9 and -14, was
implicated in the remodeling of the basement membrane during
angiogenic vessel maturation and stabilization via their negative
regulation by a distinct MMP inhibitor, the membrane-anchored
glycoprotein RECK [123]. In MMP-14 null mice, impaired postnatal
angiogenesis was demonstrated in models involving extensive
proteolytic tissue remodeling [81,117]; however, little or no evidence
was provided as to whether the observed angiogenic defects were
speciﬁcally caused by the lack MMP-14-mediated remodeling of the
basement membrane.
6.2. MMP-mediated modiﬁcations of cell surface molecules
The MMPs are able to proteolytically process a number of cell
surface receptors and process and shed soluble forms of several
membrane-bound growth factors and cytokines, which then directly
affect endothelial cell functions. This mechanism underlies the
important, although somewhat indirect functions of MMPs in tumor-
induced angiogenesis. MMP-modiﬁed or shed molecules include both
positive and negative regulators of angiogenic processes and therefore
MMP modifying/shedding functions can have opposing effects on
angiogenesis.
The processing/shedding functions of MMPs have been ascribed
for both soluble and membrane-tethered MMPs, such as MMP-1,
MMP-9 and MMP-14. Tumor-derived MMP-1 has been implicated in
the proteolytic activation of protease-activated receptor 1 (PAR-1), a
thrombin receptor, which is expressed at high levels on endothelial
cells. MMP-1 activation of PAR-1 results in the activation of MAP
kinase signaling cascades, causing transformation of the vascular
endothelium from a quiescent state into prothrombotic or pro-
inﬂammatory activated states [124,125]. MMP-9 has been shown to
release sKitL, which plays an extremely important role in tumor
growth and angiogenesis [126]. Direct MMP-14 proteolytic matura-
tion of the αv integrin subunit of αvβ3 integrin [127] can inﬂuence
tumor-induced angiogenesis through modulation of αvβ3 angiogenic
and signaling functions [128], e.g. via activation of focal adhesion
kinase [129]. Recently, MMP-14 expressed in head and neck
squamous carcinoma cells was implicated in proteolytic processing
and release of the cell membrane-tethered Semaphorin 4D, respon-
sible for the induction of blood vessel growth into s.c. implanted
angioreactors containing carcinoma cells [130].
6.3. MMP-mediated release of ECM-bound pro-angiogenic factors
MMP-mediated release and activation of matrix-bound growth
factors and cytokines, subsequently acting as pro-angiogenic factors,
is regarded as one of the major mechanisms in tumor angiogenesis
[110].
6.3.1. MMP-mediated release of VEGF
VEGF represents one of the impressive examples of pro-angiogenic
factors stored within the ECM and released by MMP proteolysis
[32,110]. A number of MMPs have been implicated in VEGF release,
although MMP-9 appears to be the most potent MMP function-
ally linked to tumor angiogenesis via VEGF-releasing mechanisms
(Fig. 1).
Functional link between MMP-9 delivered to the pre-angiogenic
site by inﬂammatory cells and the release of VEGF have been
established in several genetic mouse models of carcinoma progres-
sion. Pancreatic carcinogenesis in RIP1-Tag2 transgenic mice was the
ﬁrst model, where MMP-9, produced by inﬂammatory leukocytes,
was demonstrated to directly release VEGF and increase its bioavail-
ability [20]. Increase in bioavailability of VEGF by MMP-9, likely
produced by inﬁltrating macrophages, was also shown to contribute
to the malignant progression of ovarian carcinoma by promoting
Fig. 1.MMP-9 is a powerful proangiogenic factor acting via release of ECM-sequestered VEGF and FGF-2. MMP-9 is produced as a zymogen and requires activation before exerting its
angiogenic activity. Upon activation, MMP-9 enzyme is capable of releasing pro-angiogenic factors such as VEGF and FGF-2, which are sequestered in the ECM. Bioavailable VEGF and
FGF-2 bind to the endothelial cells expressing corresponding receptors for the angiogenic factors. Complex formation between angiogenic factors and their tyrosine kinases receptors
triggers signal transduction, which in turn leads to the angiogenic switch, involving endothelial cell reorganization and matrix and tissue remodeling.
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part scenario of MMP-9-mediated VEGF mobilization sustained by
macrophages, additional mechanisms have emerged involving
neutrophil MMP-9-mediated release of angiogenic growth factors.
Thus, impaired macrophage recruitment and therefore, production of
macrophage-derived MMP-9 to the sites of angiogenic switching,
elicited a compensatory response of MMP-delivering neutrophils,
providing an alternative paracrine support for tumor angiogenesis
[23]. Illustrating the functional role of MMP-9 delivered by neutro-
phils in the release of VEGF, ablation of neutrophil inﬁltration and
therefore, delivery of neutrophil MMP-9, resulted in the decrease of
bioavailable VEGF in angiogenic islets and suppressed the angiogenic
switch in the RIP1-Tag2 transgenic mouse model of pancreatic
progression [26].
Furthermore, MMP-9 derived from Gr+/CD11b+ cells of myeloid
lineage co-injected with colorectal MC26 tumor cells, was demon-
strated to directly promote tumor angiogenesis via an increase in
bioavailability of VEGF [24]. In addition,MMP-9 produced at the site of
primary tumor formation by recruited CD45+ myeloid cells was
shown to release ECM-sequestered VEGF during angiogenic switching
in glioblastoma [27]. Importantly, the total or bound amounts of VEGF
detected by immunohistochemistry or immunoblotting were com-
parable in tumors regardless of the presence of MMP-9, indicating
that angiogenic switching is triggered by the soluble, bioavailable
VEGF released by MMP-9 [24,27].In agreement with a requirement of MMP-9 proteolytic activity for
release of VEGF, the inhibition of MMP-9 results in the reduction of
VEGF bioavailability and a corresponding inhibition of tumor-induced
angiogenesis. Thus, the reduction in the levels of active MMP-9 due to
overexpression of thrombospondin in mice prone to generate
mammary gland tumors was concomitant with the decrease in
bioavailable VEGF and inhibition of tumor angiogenesis, and vice
versa, thrombospondin-deﬁciency resulted in higher levels of active
MMP-9 and increased VEGF/VEFGR2 complex formation [131]. In a
cervical carcinogenesis model, chemical suppression of MMP-9 in
inﬁltrating MMP-9-positive macrophages inhibited the expression
and activation MMP-9 and diminished VEGF mobilization to its
receptor [22]. Similarly, chemical repression of MMP-9 production in
a human prostate cancer model resulted in the reduced levels of
bioavailable VEGF and inhibited tumor angiogenesis in aMatrigel plug
assay [132]. Interestingly, only a few studies demonstrated that the
tumor-derived MMP-9 could also increase release of VEGF: Thus,
VEGF release in ovarian carcinoma model was attributed to the
activity of MMP-9 produced by tumor cells [87].
In contrast to MMP-9, another gelatinase, i.e. MMP-2, sharing
some substrate speciﬁcity and biochemical modes of activities with
MMP-9, does not appear to strongly contribute to release of ECM-
sequestered VEGF. Thus, knock-down of MMP-2 in mice did not
change the expression of VEGF in retinal neovascularization model
[133]. However, the ovarian carcinoma model in mice presented
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[87]. Moreover, recent analysis of proteome signatures of MMP-2-null
versus MMP-2-rescued mouse embryonic ﬁbroblasts indicated that
MMP-2 is involved in the processing of several VEGF-binding proteins,
proteolytic degradation of which ultimately results in the mobiliza-
tion of VEGF [134,135].
MMP-14 was also linked to a possible regulation of VEGF during
angiogenesis. Thus, overexpression of MMP-14 in human glioma and
breast carcinoma cells resulted in accelerated tumor growth and
angiogenesis attributed to up-regulation of VEGF in xenografts
[136,137]. In addition, MMP-3, -7, and -19 have been shown to cleave
in vitromatrix-bound isoforms of VEGF, releasing it from thematrix as
soluble fragments [138]. In this study, soluble and sequestered VEGF
appeared to exert different patterns of tumor neovascularization, i.e.
vascular hyperplasia (soluble VEGF) or vascular sprouting and
branching (matrix-bound VEGF). It has been suggested that two
forms of VEGF are involved in different signaling pathways, although
both matrix-bound and soluble VEGF bind to the same cell surface
receptor [138].
6.3.2. MMP-mediated release of FGF-2
The role of FGF-2 in tumor angiogenesis is often overshadowed by
studies implicating VEGF in the angiogenic switch and complicated by
a wide redundancy in the FGF family [139,140]. A cross-talk between
VEGF and FGF-2, their corresponding growth factor/receptor systems
along with inﬂammatory cells delivering MMPs that release ECM-
bound angiogenic factors, may play important roles in the modulation
of blood vessel growth. Functional roles for FGF-2 in angiogenesiswere
demonstrated in the chick embryo and mouse tumor angiogenesis
models [141–143]. With regard of tumor angiogenesis, modulation of
FGF-2/FGFR2 system showed overall correlative effects on tumor
neovascularization. Thus, inhibition of FGF-2 and interferencewith the
FGFR2 pathway concomitantly decreased tumor angiogenesis, while
FGF-2 overexpression or exogenous delivery of FGF-2 resulted in the
accelerated development of new blood vessels in tumors [142].
FGF-2 is found in association with endothelial basement mem-
branes and appears to be sequestered in the ECM as a stable but
inactive form, requiring release for biological activity. The mechan-
isms of FGF-2 release from ECM include proteolytic cleavage of
heparan sulphate proteoglycans, a major anchor of FGF-2, by plasmin,
thrombin or MMPs [144,145] (Fig. 1). MMP involvement in the FGF-2-
mediated angiogenesis was suggested in the corneal neovasculariza-
tion model in MMP-14 knockout mice, where the lack of MMP-14,
either directly or through impaired MMP-2 activation, resulted in a
complete inhibition of angiogenesis response to FGF-2 [81]. In
agreement with this suggestion, MMP-2 proteolytic activity was
implicated in the release of FGF-2 from the cell-ECM interface in the
lens capsule model [146]. Recently, MMP-9 has been shown to
directly induce release of FGF-2 and mediate FGF-2-dependent
physiologic angiogenesis in the chick embryo model [143].
Despite a general acceptance that FGF-2 release from the ECM is a
prerequisite for exhibiting its biological function, the experimental
evidence implementing such release mechanism in angiogenesis in
vivo and especially in tumor-induced angiogenesis is limited. A
possible explanation may be in that an initial blocking of the VEGF/
VEGFR2 pathway must ﬁrst occur before switching to the alternative
FGF/FGFR pathway of angiogenesis. This switching mechanism was
demonstrated in the pancreatic carcinogenesismodel, where develop-
ment of late-stage tumors, emerging after VEGFR2 blockade and initial
tumor suppression, was associated with reactivation of VEGF-
independent angiogenesis induced by the members of FGF family
[147]. In this regard, the natural dependence of CAM vascularization
on FGF-2 rather than on VEGF [148], might have allowed for the
demonstration of MMP-9-mediated FGF-2 release and involvement of
FGF-2/FGFR2 pathway elicited by MMP-9 proteolytic activity in the
chick embryo angiogenesis model [143].6.4. MMP-mediated generation of anti-angiogenic factors
The existence of a ﬁne balance in the regulation of pleiotropic
functions of MMPs is highlighted by the fact that the same individual
MMPs clearly exerting pro-angiogenic activity can be implicated as
well in an anti-angiogenic “conspiracy”. In addition to the proteolytic
release of matrix-bound pro-angiogenic factors, MMPs have been also
demonstrated to generate a number of anti-angiogenic molecules
[121]. Therefore, different cell types responsible for delivery and
production of certain MMPs in the pre-angiogenic site could present
quite different scenarios for tumor-associated angiogenesis.
Several MMPs, including MMP-2, -7, -9 and -12, are capable of
cleaving plasminogen and producing angiostatin, a circulating poly-
peptide fragment with anti-angiogenesis capabilities [149–151].
Macrophage metalloelastase, MMP-12 proved to be one of the most
efﬁcient angiostatin-producing MMPs [152]. In human hepatocellular
carcinomas, high expression of MMP-12 was associated with high
levels of angiostatin and diminished vascularization [153]. Mice
lacking α1 integrin and expressing high plasma levels of MMP-9 and
MMP-9-generated angiostatin, demonstrated auto-inhibition of
tumor angiogenesis [154,155], suggesting that diminishment of
MMP activity by MMP inhibitors may contribute to the acceleration
of tumor progression.
Endostatin, another reported inhibitor of blood vessel growth, was
shown to be produced in vitro from basement membrane type XVIII
collagen by several MMPs such as MMP-3, -7, -9, -12, and -20
[150,151,156,157]. However, MMP-1, -2, -8 and -12 failed to show any
signiﬁcant activity against collagen XVIII [158]. Anti-angiogenic
mechanisms of endostatin involves direct inhibition of endothelial
cell proliferation, migration and capillary formation, in part via
binding to α5β1 integrin and blocking of downstream phosphoryla-
tion of FAK [159]. Interestingly, in a study where endostatin inhibited
human tongue carcinoma invasion and dissemination in the chick
embryo CAM model, it was also shown to block activation of several
MMPs, including MMP-9 and -13 [151], i.e. those MMPs which are
initially involved in the production of endostatin.
The anti-angiogenic role of select MMPs, e.g. MMP-9, also has been
attributed to their ability to generate tumstatin from the α3 chain of
collagen IV [150,151,160]. Decreased levels of circulating tumstatin in
MMP-9 null mice were linked to accelerated growth and pathological
angiogenesis of subcutaneously developing Lewis lung carcinomas
[160]. Although anti-angiogenic effects of tumstatin in the in vitro
settings are direct and involve direct binding to αvβ3 integrin
expressed on endothelial cells and inhibition of their proliferation
[160], it is difﬁcult to explain why MMP-9 deﬁciency in many in vivo
mouse models has been repeatedly associated with a substantial
inhibition of tumor-induced angiogenesis (due to the lack of pro-
angiogenic MMP-9), rather than with accelerated tumor neovascular-
ization (due to the absence of MMP-9-generated tumstatin or other
MMP-9-cleaved angiogenesis inhibitors). There is also not much
experimental evidence to mechanistically link the enzymatic activity
of MMPs required for generation of the speciﬁc anti-angiogenic
factors in vivo with a decrease in a MMP activity observed during the
switching-off of angiogenesis.
7. Cell surface localization of soluble MMPs in the
angiogenic tissue
Speciﬁc cellular and pericellular localization is viewed as a means
to compartmentalize MMPs and regulate their activity in vivo.
Understanding MMP functions during tumor-induced angiogenesis
in vivo depends on identiﬁcation of the mechanisms of how the
released, secretory MMPs are activated and targeted to the right
location and how MMP activity is regulated at the pericellular space.
Initially, localized proteolytic activity of soluble MMPs was asso-
ciated with the surface expression of membrane-tethered MMP-14
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tion of cell surface MMP-14 [72,100,101], facilitates compartmentaliza-
tion of proMMP-2 and it subsequent activation at speciﬁc areas such as
the leading edge of tumor and endothelial cells [115]. MMP-2 zymogen
also binds to theαvβ3 integrin on activated endothelial cells, whichwas
reported to facilitate proMMP-2 activation [162]. Although initially
described as αvβ3-mediated [162], the activation of proMMP-2 by
αvβ3-expressing cells is actuallymediatedbyMMP-14 since tumor cells
expressingαvβ3 but noMMP-14 do not generate activatedMMP-2, but
gain this ability after transfection with MMP-14 cDNA [163,164]. The
functional role of cell surface bound MMP-2 in tumor-induced
angiogenesis was highlighted in a study where lentiviral delivery of a
noncatalytic fragment of MMP-2 (PEX) inhibited tumor-induced
angiogenesis and tumor growth in a nude mouse model [85].
Another example of docking of soluble MMPs to cell surface
molecules that lack any proteolytic activity, but promote zymogen
activation through autolytic cleavage, is provided by the binding of
MMP-9 to the hyaluronan receptor CD44 [165]. By gelatin zymo-
graphy, MMP-9 bound to CD44 was identiﬁed as an activated enzyme
(i.e. 82 kDa processed form), but the mechanism of zymogen
activation and whether it occurs prior to CD44 binding remained
unresolved. CD44-facilitated activation of MMP-9 resulted in modiﬁ-
cation of tumor invasion and angiogenesis, likely via activation of
latent TGFβ [166]. A membrane-bound form of MMP-9 detected in a
variety of normal and tumor cells, including neutrophils, endothelial,
and carcinoma cells, constitutes only a small fraction of the total
enzyme, while the major soluble form has long been regarded as the
biologically relevant formof the proteinase [167]. Itwould be plausible
to suggest that the cell surface-localized portion of MMP-9 might
represent the enzyme bound to a putative membrane-tethered pro-
tease, which directly activates the MMP-9 zymogen. This membrane-
associated portion of MMP-9 enzyme can then serve as a potent
catalyst of a MMP-9 activation cascade. However, a study in which
human MCF-7 breast carcinoma cells were generated to express
MMP-9 either as a constitutively active, membrane-anchored enzyme
or as a secreted proenzymeprovided experimental evidence in favor of
a view that it is the secreted form of MMP-9 which promotes tumor
growth and the angiogenic switch in s.c. xenografts [168]. Importantly,
this study also demonstrated that enhancedMMP-9-dependent angio-
genesis required activation of proMMP-9 (by yet unidentiﬁed in vivo
activators) and the activity of MMP-9 enzyme. Furthermore, the
inhibition of MMP-9 activation and activity resulted in the decrease of
tumor angiogenesis concomitant with reduced microvessel density.
All these results provide additional evidence for the critical role that
MMP-9, more than any other MMP, plays in tumor angiogenesis.
8. MMP-9 and the recruitment of bone marrow-derived
progenitor cells to the sites of tumor angiogenesis
and vasculogenesis
A rapidly increasing volume of studies indicates that in addition to
local cellular resources to build new blood vessels, tumor neovascu-
larization also depends on circulating cell progenitors, mainly of bone
marrow origin,mobilized into the circulation by cytokines and growth
factors such as VEGF [169,170]. These circulating progenitor cells are
recruited by primary tumors in a MMP-9-dependent manner through
a complex system of chemokines [9,10,171,172].
8.1. MMP-9-dependent mobilization of angiogenic and vasculogenic
progenitor cells
Initial experiments have demonstrated that MMP-9, induced in the
bone marrow by circulating cytokines such as SDF-1, VEGF or G-CSF,
releases soluble Kit ligand (sKitL), which in turn, permits the transfer of
quiescent, c-Kit-positive endothelial (VEGFR1+) and hematopoietic
(VEGFR2+) stem and progenitor cells from the osteoblastic zone to thevascular zone. Translocation to the vascular-enriched zone induces pro-
liferation and differentiation of hematopoietic progenitor cells (HPCs)
and endothelial progenitor cells (EPCs) and their mobilization to the
peripheral circulation [126,173]. Such mobilization of bone marrow
derived HPCs and EPCs was inefﬁcient in MMP-9 null mice due to the
lackof sKitL release, conﬁrming the critical dependence of theprocess on
MMP-9 activity, although the precise cellular source ofMMP-9 responsi-
ble for release of sKitL was not identiﬁed in this study. The requirement
of MMP-9 activity for the mobilization of HPCs was also conﬁrmed by
administrating a synthetic MMP inhibitor in vivo, which blocked
chemokine-induced mobilization in MMP-9-competent mice [126].
In the study where mobilization of HPCs was induced by a com-
bination of G-CSF and GROβ, the cellular source of MMP-9 required for
HPC egress from bone marrow into circulation surprisingly, but import-
antly, was attributed to neutrophils [97]. HPC mobilization correlated
with elevated levels of neutrophil-derived MMP-9 in marrow and was
blockedby a function-blocking anti-MMP-9mAb, preventing activationof
proMMP-9. The lack of HPC egress in response to chemokines in MMP-9
knockout mice also conﬁrms MMP-9-dependency of HPCs mobilization
[97].
8.2. MMP-9-mediated recruitment of bone marrow-derived
progenitor cells
BothHPCs andEPCs,mobilized into the circulation frombonemarrow,
can participate in neovascularization at the primary tumor site. The
relative contribution of each cell type could be dictated by the cytokine
repertoire and matrix composition of a particular tumor type
[10,174,175]. Circulating HPCs recruited to the site of adult neovasculari-
zation are usually distributed around blood vessels with clear afﬁnity to
retain a close proximity to vessels, and do not incorporate into the
endothelial liningof thebloodvesselwall [170].However, tumor-retained
HPCs can functionallymimic EPCs by enhancing tumor angiogenesis [28].
In contrast, circulating EPCs are intimately integratedwithin endothelium
and often are found colocalizing with endothelial cells [10,176].
Recent studies also indicated that more mature cell subpopula-
tions belonging to myeloid (CD45+) or myelomonocytic (CD11b+)
lineages could be mobilized from bone marrow and contribute to
tumor angiogenesis. Thus, mobilized CD45+ myeloid cells were
shown to include MMP-9-positive monocytic cells which can be
traced to the site of glioblastoma development, where they were
found randomly distributed within the tumor [27]. In this orthotopic
glioblastomamodel, the recruitment of bone marrow-derived CD45+
myeloid cells is driven by HIF1α, the direct effector of hypoxia,
whereas MMP-9 activity of recruited MMP-9-positive cells has been
demonstrated to be essential and sufﬁcient to initiate the angiogenic
switch. The mechanism of angiogenic switching included the earlier-
discovered MMP-9-mediated release of soluble, bioavailable VEGF
[27]. Besides releasing VEGF, the MMP-9 produced by HPCs recruited
to neoangiogenic sites in the primary tumors, positively contributes to
tumor angiogenesis by increasing the bioavailability of stem cell
active chemocytokines, including SDF-1 and sKitL [177].
8.3. The role of MMP-9 in tumor vasculogenesis
In addition to tumor-induced angiogenesis involving endothelial cell
sprouting and capillary formation from pre-existing blood vessels,
recent years brought about data, which have led to a new concept of
tumor vasculogenesis as an alternative mechanism of tumor vessel
generation. This concept is supported by the ﬁndings demonstrating
that at a certain stage of tumorigenesis, circulating bone marrow-
derived cells, including HPCs, EPCs and pericyte progenitor cells (PPCs),
may contribute to the assembly of new tumor blood vessels. Immuno-
histological studies demonstrated that the recruited cells were often
found being incorporated into vasculature wall and observed in the
perivascular regions of the endotheliumor colocalizedwith endothelial
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genitor populations and the expression of lineage-speciﬁc markers are
not well established and remain controversial [10,170,178,179], it
appears that tumor vasculogenesis requires the expression of MMP-9
for efﬁcient integration of recruited cells to the tumor vasculature.
Thus, in the HIF1αmodel of glioblastoma development, the expression
of MMP-9 enabled EPCs (and apparently also PPCs) to incorporate into
tumor vessels and sustain their pericyte coverage [27].
An alternative scenario of tumor vasculogenesis was demonstrated
in amodel systemwheremammary tumorswere transplanted intowild
type orMMP-9 knockoutmice pre-irradiated to prevent angiogenesis at
the site of implantation [28]. In this model, genetic depletion of MMP-9
abrogated tumor growth and development of new, vasculogenic blood
vessels. However in wild-type recipients, MMP-9-positive, bone
marrow-derived CD11b+ myelomonocytic cells, which essentially are
HPCs, but not EPCs, inﬁltrated the tumors and were responsible for
tumor growth and development of immature blood vessels [28].
9. MMPs at the metastatic site: MMP-9 and the establishment of
the pre-metastatic niche
In addition to the initial concept of mobilization and recruitment of
bone marrow-derived cells to the primary tumor, a novel concept has
recently emerged whereby the primary tumor induces the recruit-
ment of HPCs to distant sites, where permissive pre-metastatic niches
are created, providing a favorable soil to seed the tumor cells which
will eventually escape the primary tumor [180]. The contribution of
bonemarrow-derived HPCs in the generation of pre-metastatic niches
was analyzed in a spontaneous metastasis model where Lewis lung
carcinoma or B16 melanoma cells were implanted subcutaneously
and allowed to form primary tumors, eventually metastasizing to the
distant sites [181]. It has been demonstrated that primary tumors
produced soluble factors which by unknown mechanisms induced
recruitment of bone marrow-derived HPCs to preferential metastatic
organs. Of critical importance was the identiﬁcation that HPC arrived
to the putative metastatic site and generated a permissive niche well
before tumor cell dissemination. Interestingly, that in this model EPCs
did not contribute to the generation of pre-metastatic niches, but
rather accompanied the arriving tumor cells. In addition to other
critical factors such as the expression of integrin α4β1, apparently
required for adhesion of HPCs to the niche ﬁbronectin, the whole
process of niche generation appeared to depend on MMP-9 produced
by HPC clusters. The functional role of MMP-9 in establishing the pre-
metastatic niche was conﬁrmed by using MMP-9 null mice demon-
strating impaired HPC cluster formation and reduced metastatic
spread. However, the precise catalytic activities of MMP-9 during
generation of and within the pre-metastatic niche remain unknown,
although the breakdown of basement membranes and the altering of
local microenvironment by releasing sKitL and VEGF have been
proposed [180,181]. The TIMP-1 status of MMP-9 delivered by these
critical HPCs has yet to be determined.
10. Biochemical mechanisms underlying the distinct angiogenic
potency of MMP-9
An extensive volume of experimental evidence, much of which has
alreadybeendiscussed inprevious sections of this review, indicates that
MMP-9 is clearly one of the most potent pro-angiogenic MMPs. The
direct contributionofMMP-9 to angiogenesis and vascular performance
is thought to involve the catalytic activity of the enzyme resulting either
in the cleavage of ECM components such as native and denatured
collagens [93,182,183], processing of various cytokines and chemokines
[47,50], or release of angiogenic growth factors such as VEGF
[20,24,26,27,52,132,138] and also FGF-2 [143]. Although MMP-9 has
been strongly associatedwith angiogenesis, its direct catalytic reactions
in vivo and regulation of its activity during the angiogenic processremain largely undeﬁned. Moreover, the actual in vivo substrates for
MMP-9's pro-angiogenic activity have not been demonstrated (Fig. 1).
It has been generally accepted that at the site of angiogenic switch,
MMP-9 is produced mainly by inﬂammatory monocytes [17,38,43].
However, inﬂammatory neutrophils could serve as an immediate and
major source of MMP-9 in pre-angiogenic tissue [184]. Recent ﬁndings
from Hanahan's laboratory demonstrated a close link between the
presence of MMP-9-expressing neutrophils and the onset of the angio-
genic switch in developing tumors [23,26,185]. The close association of
neutrophil-derivedMMP-9with angiogenesis was also found in tumors
where monocyte inﬂux had been greatly diminished by speciﬁc block-
ing reagents and a compensatory neutrophil response was evoked [23].
The functional role of distinct inﬂammatory cells and their associated
MMPs during physiologic and tumor-induced angiogenesis was demon-
strated by using a quantitative in vivo angiogenesismodel [186], modiﬁed
from the original assay described by Folkman and colleagues [187]. In this
model angiogenesis involves the inﬂux of inﬂammatory cells, including
monocyte/macrophages andavianneutrophils, and is facilitatedbyMMPs
released or producedby these cells, i.e.monocyteMMP-13 andneutrophil
MMP-9 [188,189]. A question remained, however, as to whether inﬂa-
mmatory cell-derived MMP-9 itself is uniquely pro-angiogenic in vivo.
We have recently probed the regulatory mechanisms determining
the pro-angiogenic status of neutrophil MMP-9 and demonstrated a
direct functional roleof neutrophils andneutrophilMMP-9 inphysiologic
angiogenesis. By employing a modiﬁed chick embryo chorioallantoic
membrane (CAM) angiogenesis assay, it was demonstrated that human
neutrophil proMMP-9 is potently angiogenic at low to sub nanomolar
levels [48]. This angiogenic proMMP-9 is released from human neu-
trophils in a unique, TIMP-free form, which is in contrast to the TIMP-1-
complexed proMMP-9 produced by most other cell types, including
macrophages, B lymphocytes and tumor cells [49,56]. The potent angio-
genic characteristics of neutrophilMMP-9 can be attributeddirectly to its
TIMP-free nature and also to its immediate availability at relatively high
concentrations upon granulae release from the stimulated neutrophils
(Fig. 2). In angiogenesis-reconstitution experiments, the substitution
of neutrophil TIMP-free proMMP-9 with equimolar and even 20-fold
molar excess levels of the neutrophil proMMP-9/TIMP-1 complex has
conﬁrmed that it is the TIMP-free nature that determines the potent pro-
angiogenic potential of neutrophil proMMP-9 [48,143].
These ﬁndings also demonstrate that neutrophil MMP-9 induces a
differential inﬂux of additional protein components into angiogenic
tissueandproteolytically causes a release of bioactivebasic FGF (FGF-2).
The released bioavailable FGF-2, acting through its cognate receptor
FGFR2, is the actual inducer of angiogenesis that functions downstream
of the released proMMP-9, which is very effectively activated in vivo
because of its TIMP-free status. The TIMP-free MMP-9/FGF-2 pathway
of angiogenic induction was conﬁrmed to operate not only in the chick
CAM assay, but also in vivo in a mammalian setting, i.e. in a mouse
angiotube assay recently established in our laboratory [143,190].
Overall our results indicate that neutrophil TIMP-free proMMP-9
is potently and uniquely angiogenic and is distinct from the low- or
non-angiogenic proMMP-9 secreted by other cell types, including
activatedmacrophageswhich appear to produce proMMP-9molecules
stoichiometrically bound to TIMP-1. In addition, even upon stimulation
required for the induction of expression and secretion of MMP-9 by
monocytes/macrophages, the levels of MMP-9 production by these
cells are much lower than those provided by de-granulating neutro-
phils. It has been determined that in 30min 1×106 neutrophils release
5 to 20 timesmore proMMP-9 than1×106 PMA-stimulatedmonocytes
secrete over 24-48 hours (our unpublished observations). Therefore, it
appears that inﬂammatory neutrophils uniquely provide immediate
and high levels of the angiogenic TIMP-free proMMP-9 [48,143]. How-
ever, it is unclear mechanistically how neutrophil proMMP-9 becomes
activated and when and how active neutrophil MMP-9 enzyme does
induce angiogenesis. Identiﬁcation of the relevant in vivo substrate(s)
of angiogenic MMP-9 will help clarify these unanswered issues.
Fig. 2. Efﬁcient and rapid activation of neutrophil proMMP-9 due to its unique TIMP-free status. Neutrophils synthesize and storeMMP-9 in their secretory granules, readily available for
release on demand. Since TIMP-1 production in neutrophils is very low or even undetectable, MMP-9 zymogen is released in the TIMP-free form, immediately accessible to proteolytic
activation. Therefore, activation of TIMP-freeneutrophilMMP-9 is relatively rapid andactivatedMMP-9 enzymebecomes readily available to trigger the angiogenic switch. In contrast to
neutrophils, stimulatedmonocytes/macrophages and tumors cells synthesizeMMP-9 de novo. Usually, induction ofMMP-9 is concomitant with an increased expression of TIMP-1 and
therefore, MMP-9 zymogen at least partially is complexed with TIMP-1. Complexing with TIMP-1 slows activation of MMP-9 zymogen and makes it relatively inefﬁcient as compared
with activation rates of TIMP-free MMP-9. This delayed activation might make monocyte and tumor-derived MMP-9 less efﬁcient in the induction of angiogenesis.
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malignant angiogenesis
The multiple and sometimes contrasting aspects of diversiﬁed
functionalitywithin theMMP family in angiogenesis-relatedprocesses
imply that MMPs, acting as a cohort of enzymes or as individual
enzymes, exhibit pleiotropic roles in tumor neovascularization. Below,
we will highlight contrasting and synergistic functions of individual
MMPs as they relate directly to malignant angiogenesis (Table 3).
11.1. MMP-1
MMP-1, an interstitial collagenase, can be produced by inﬂammatory
monocytes/macrophages inﬁltrating the primary tumors as well as by
tumor cells themselves. In breast cancer, MMP-1 belongs to a family of
metastasis signature genes governing lung metastasis [191]. In combi-
nation with MMP-2, the cyclooxygenase COX-2 and the EGFR ligand
epiregulin, MMP-1 can regulate the structure of the vascular network in
the primary tumor and promote the formation of the dilated, tortuous
and leaky blood vessels, typical for aggressive primary tumors [192].
While single down-regulation of the above-mentioned genes in MDA-
MB-231 breast carcinoma cells did not considerably alter the overall
vascular network in the primary tumor, the combined knock-down ofall 4 genes attenuated vascular permeability and also diminished the
ability of escaped tumor cells to extravasate from the lung capillaries.
These combined effects resulted in substantially inhibited lung metas-
tasis [191,192], suggesting a cooperative, possibly synergistic role for
MMP-1.
11.2. MMP-2
In the above-described model, single down-regulation of MMP-2
in tumor cells did not produce signiﬁcant effects on tumor angiogen-
esis and cancer progression, demonstrating a relative lack of tumor-
derivedMMP-2 involvement in angiogenesis [192]. Moreover, MMP-2
deﬁciency did not affect the course of angiogenic switching in the
pancreatic carcinoma islets [20] nor did it affect angiogenesis in
malignant keratinocyte transplants [30], thus questioning the puta-
tive angiogenic capabilities of stromal MMP-2 in vivo. However,
reduced angiogenesis in subcutaneous tumors developing from the
B16-BL6 melanoma or Lewis lung carcinoma cells was reported in
MMP-2 knockout mice [193], highlighting a possible functional role of
stromal MMP-2 in tumor neovascularization. In addition, targeting of
MMP-2 with soluble PEX also reduced tumor angiogenesis in the pre-
established s.c. melanoma transplants [85]. Overall, these opposing
results may indicate that MMP-2 contribution to tumor angiogenesis
Table 3
Evidence for the roles of individual MMPs in tumor angiogenesis.
MMP Evidence
MMP-1 Correlative evidence indicating synergism of tumor MMP-1 with epiregulin, MMP-2, and COX2 [192].
MMP-2 Conﬂicting evidence for pro-angiogenic role [193] or the lack of contribution to angiogenesis [20,192], depending on the model of angiogenesis used in MMP-2
knockoutmice. Evidence for synergismof stromalMMP-2withMMP-9 [30]. Contrastingevidence for ananti-angiogenic role via productionof anti-angiogenic factors.
MMP-3 Conﬂicting evidence indicating the lack of contribution to angiogenesis [30] or protective role in leukocyte-mediated angiogenesis depending on the model used
in MMP-3 knockout mice [196].
MMP-7 Conﬂicting evidence indicating the lack of contribution to angiogenesis in MMP-7 knockout mice [29] versus direct pro-angiogenic role of the recombinant
MMP-7 enzyme [198]. Contrasting evidence for an anti-angiogenic role via production of anti-angiogenic factors.
MMP-8 Indirect and conﬂicting evidence suggesting a putative pro-angiogenic role via promoting neutrophil inﬁltration [202] or anti-angiogenic role via decreasing
inﬂammation [201].
MMP-9 Causal evidence for a role of MMP-9 in vascularization in knockout mice [203]. Direct evidence for pro-angiogenic role using rescue of MMP-9 knockout mice
[20,21,24,25,52,76]. Strong evidence for monocyte MMP-9 by inhibition of tumor inﬁltration with zoledronic acid [22]. Strong evidence for neutrophil MMP-9 by
employing isolated neutrophil populations in tumor-induced angiogenesis in CAM model [189], or by ablation of MMP-9-delivering neutrophils [26] and
eliciting neutrophil response [23] in transgenic mouse models. Evidence for synergism of tumor MMP-9 with cathepsin B and uPAR [205-207,240]. Contrasting
evidence for anti-angiogenic roles via generation of anti-angiogenic factors.
MMP-12 Evidence for anti-angiogenic role via generation of angiostatin [208]. Direct evidence for anti-angiogenic function in MMP-12 null mice [209, 210] or in models
employing tumor cells overexpressing MMP-12 [153].
MMP-14 Correlative evidence for a pro-angiogenic role in model systems employing MMP-14-overexpressing tumor cells [130,136,137] or MMP-14-speciﬁc function-
blocking antibody [212].
MMP-19 Conﬂicting evidence indicating a pro- or anti-angiogenic role of MMP-19 depending on angiogenesis setting [213].
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the site of primary tumor formation.
11.3. MMP-3
MMP-3 (stromelysin-1) represents one of the MMPs with clearly
pleiotropic functionality in tumor progression. MMP-3 is found almost
exclusively in the tumor stroma and is expressed by ﬁbroblasts,
endothelial cells and inﬁltrating leukocytes. In transgenic mice, MMP-
3 has been demonstrated to act as a natural mammary tumor promoter
[194] andoverexpressionofMMP-3positively contributed tomammary
carcinogenesis [195]. Surprisingly, the lack of MMP-3 alone or in
combination with MMP-9 deﬁciency did not affect tumor vasculariza-
tion in malignant keratinocyte transplantation model [30]. However, a
protective role for MMP-3 was demonstrated in a squamous cell
carcinoma model, where the lack of MMP-3 in the host stroma in null
mice led to elevated tumor growth [196]. Tumor progression in this
model was inversely associated with the leukocyte inﬁltration,
speciﬁcally with an overall reduction in tumor-associatedmacrophages
and neutrophils, suggesting that expression of MMP-3, probably in
stromal ﬁbroblasts, might regulate leukocyte inﬁltration and thus
indirectly inﬂuence inﬂammatory leukocyte-mediated angiogenesis.
11.4. MMP-7
MMP-7(matrilysin) isproducedbyavarietyof cells and its association
with cancermetastasis andprogressionwasdemonstrated in anumber of
studies [197]. In immunodeﬁcient mice, exogenously delivered recombi-
nant MMP-7 was demonstrated to induce human colon tumor
angiogenesis through direct stimulation of endothelial cell proliferation
[198]. In contrast, in the multistage MMTV-PyVT mammary carcinogen-
esismodel, the lack of MMP-7 in knockoutmice did not have an effect on
the development of primary mammary tumors or lung metastasis [29].
11.5. MMP-8
MMP-8 (collagenase-2), produced mainly by neutrophils, is a
potent protease, which exhibits strong protective functions during
chemically induced skin carcinogenesis [199] and also in breast cancermetastasis models [200]. However, it remained unclear whether the
anti-tumor effects of MMP-8 were associated with the modulation of
tumor angiogenesis. The data obtained in MMP-8 null mice indicated
that MMP-8 appears as contributing to the resolution of inﬂammation
[201]. More recently it has been demonstrated that by generating
chemotactic factors during inﬂammation, MMP-8 can also promote,
apparently in a paracrine fashion, neutrophil migration through the
collagenous stroma of cornea [202]. Therefore, any putative role of
MMP-8 in angiogenesis will likely be linked to MMP-8-mediated
regulation of the inﬂammatory response.
11.6. MMP-9
The initial observation that knockout of MMP-9 in mice leads to
developmentally delayed angiogenesis in bone-growth plates [203],
provided a strong link of this MMP to vascular angiogenesis. This
ﬁnding was followed by the demonstration of impaired tumor
neovascularization in several metastasis models. Thus, microvessel
density in intraosseous tumors developing from the human prostate
cancer cell line PC-3 in RAG-1/MMP-9 double knockout mice is lower
compared with control MMP-9-positive, RAG-1-negative counterpart
[204]. The genetic ablation of MMP-9 abrogated angiogenic switching
during carcinogenesis of pancreatic islets in transgenic RIP1-Tag2
model [20]. Similarly, the ablation of MMP-9-delivery to primary
tumors by genetic manipulations involving other than MMP-9 genes,
e.g. by ablation of CSF-1 [40], by chemical treatments, e.g. with
bisphosphonate [22], or using antibodies against granulocytes, e.g.
anti-Gr-1 mAb [26], provided additional strong links supporting the
concept thatMMP-9 is anMMPwith unique pro-angiogenic properties.
The proof-of-principle providing a direct functional link between
MMP-9 and the formation, structure and remodeling of new blood
vessels, however, came from the phenotypical rescue of vasculogenic
and angiogenic defects manifested in MMP-9 null mice by the
transplantation of wild-type bone marrow [21,25,28,52,76]. All
these studies have unambiguously demonstrated that MMP-9,
delivered to the primary tumors by the progenies of donor
hematopoietic cells, directly contributes to tumor neovascularization.
The rescue of impaired angiogenesis in colorectal tumors developing
in the MMP-9-deﬁcient mice can also be achieved by a co-injection of
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donor mice used as a source of MMP-9-delivering cells [24]. The
precise lineage of thesemyeloid cells, i.e. their terminal differentiation
into monocytes or neutrophils has not been deﬁned. Noteworthy, the
induction of angiogenesis in vivo by puriﬁed preparations of TIMP-
free MMP-9 provided evidence that neutrophil MMP-9 itself is a
potent angiogenic factor [48,143].
In addition to genetic ablation of MMP-9 in knockout mice, down-
regulation of MMP-9 expression in tumor cells provided valuable
information regarding essential functions of tumor-derived MMP-9 in
tumor neovascularization. Inhibition of MMP9 gene expression in
conjunction with the downregulation of cathepsin B or uPAR in
glioblastoma cells resulted in reduction of tumor growth and
angiogenesis in the mouse dorsal window assay [205–207]. Anti-
angiogenic effects of MMP-9 deﬁciency in tumor cells were mani-
fested in the disruption of capillary network formation, suggesting
that the MMP-9-mediated proteolytic modiﬁcations of ECM are
required for proper blood vessel formation.
Of signiﬁcance to the pleiotropic nature of MMPs, MMP-9may also
exhibit protective functions in tumor angiogenesis, which are
associatedmostly with its ability to proteolytically generate inhibitors
of angiogenesis. Those protective properties of MMP-9 have been
discussed in Section 6.4.
11.7. MMP-12
MMP-12 (macrophage metalloelastase), expressed almost exclu-
sively in macrophages, represents an MMP with cancer protective
roles. The protective function of MMP-12 in tumor progression was
suggested by the ability of this MMP to generate the anti-angiogenic
fragment angiostatin from plasminogen [208] and the resulting anti-
angiogenic effects of angiostatin (previously discussed in Section 6.4).
This suggestionwas further afﬁrmed by suppression of primary tumor
growth and halted angiogenesis in the mice grafted with melanoma
cells overexpressing MMP-12 [153]. In agreement with the anti-
angiogenic function of MMP-12, MMP-12 null mice demonstrated
increased tumor growth and blood vessel formation in the orthotopic
Lewis lung carcinoma model and decreased levels of circulating
angiostatin [209]. Similar results were obtained in the Lewis lung
carcinoma model employing MMP-12 null and wild type mice, where
presence of MMP-12was associated with decreased tumor-associated
microvessel density, resulting in suppressed growth of lung metas-
tasis [210]. Interestingly, some MMP-12-mediated effects on tumor
growth and angiogenesis were independent of theMMP-12-mediated
production of angiostatin. That the macrophages express a potent
anti-angiogenic MMP, i.e. MMP-12, along with the production of pro-
angiogenic MMPs, emphasizes the notion that depending on the
relative composition of the inducedMMP secretate, this inﬂammatory
cell type might exhibit opposing angiogenic roles.
11.8. MMP-14
Although embryonal vasculogenesis appeared to be MMP-14-
independent [83], apparent defects in neonatal angiogenesis of
MMP-14 knockout mice have been observed, however mostly in ex
vivo and in vitro models [117]. Angiogenic defects in early neonatal
development ofMMP-14 null micewere described only in a few in vivo
models, e.g. a corneal angiogenesis assay [81]. Due to the early lethality
of mice deﬁcient in MMP-14, limited evidence has accumulated
supporting the role ofMMP-14 in tumor-induced angiogenesismodels.
A few studies providing some evidence for the pro-angiogenic role of
tumor MMP-14 in angiogenesis in vivo, demonstrated the enhanced
vascularization in tumors over-expressing MMP-14, which was clearly
linked to up-regulation of VEGF [136,137]. In vitro analyses of
mechanisms, which could underlie MMP-14-mediated enhancement
of tumor angiogenesis, implicated activation of Src tyrosine kinases byMMP-14 [120] or release and reactivation of VEGF from the connective
tissue growth factor [211]. Another mechanism for regulation of
tumor-induced angiogenesis by tumor MMP-14 involves release of
Semaphorin 4D, a potent promoter of neovascularization [130]. Recent
ﬁndings demonstrated that selective inhibition of MMP-14 with a
function-blocking mAb, generated by phage display technology,
inhibited tumor-induced angiogenesis and slowed tumor progression
and metastasis [212].
11.9. MMP-19
MMP-19 is reported to be expressed in normal human epidermis,
but down-regulated during malignant transformation and dedifferen-
tiation [213]. Following acute inﬂammation or injury, MMP-19 was
found expressed in the endothelial cells of synovial capillaries [214]
and was also reported to be expressed in peripheral blood monocytes
[53]. InMatrigel plugs, tumor-induced angiogenesis is accompanied by
MMP-19 expression in the host mesenchymal cells but not by
endothelial capillary cells or CD11b-positive inﬂammatory cells [213].
The initial observations in MMP-19 null mice indicated that a lack of
MMP-19 resulted in a decreased susceptibility to skin tumors
chemically induced by carcinogens [215], i.e. pointing only to a positive
role of MMP-19 in carcinogenesis. However, during FGF-2-induced
angiogenesis inMatrigel plugs containingmalignant keratinocytes and
implanted into MMP-19 null mice, host MMP-19 deﬁciency was
associated with an increased early angiogenic response and enhanced
tumor invasion [213]. Therefore, MMP-19 can also function as a
negative regulator of early steps of tumor angiogenesis and invasion.
12. MMPs as targets of anti-angiogenic therapy: interfering with
pleiotropic functions
Inhibition of angiogenesis duringmalignantprogressionby targeting
of VEGF/VEGFR and FGF-2/FGFR2 pathways with corresponding
therapeutics was considered for a long time the most reasonable way
for controlling metastatic disease at the level of primary tumor devel-
opment [185,216,217]. However, from the initial reports that tumors
mightbecomerefractory to anti-VEGF therapy, the concept has emerged
that anti-angiogenic therapy may result in increased malignant
progression. In this regard, the most recent studies have presented
evidence indicating that targeting the VEGF pathway in pancreatic
neuroendocrine carcinomas and glioblastomas in mice actually
increased local invasion and distant metastasis [218]. Similarly, in
metastasis models involving intravenous injection of cells or removal of
orthotopic primary tumors, treatments with potent anti-angiogenic
VEGFR/PDGFR inhibitors were shown to accelerate metastasis of breast
cancer and melanoma cells [219]. In addition, VEGF has been recently
described as a negative regulator of pericyte function and vessel
maturation [220] and its deletion inmyeloid cellswas shown to increase
pericyte coverage and normalize tumor vasculature [221]. In these
studies, ablation of VEGFwas associatedwith accelerated tumorigenesis
and tumor progression, which might provide, at least in part,
mechanistic explanation for undesirable consequences of anti-VEGF
therapies. These disillusioning ﬁndings once again indicate that anti-
angiogenic therapy either with inhibitors targeting directly endothelial
cells or targeting the molecules triggering the angiogenic switch could
have different outcomes in the course of malignant progression.
Since MMPs are potent triggers and contributors of the angiogenic
switch, it was a long-standing notion that blocking MMPs at the site of
tumor development would substantially inhibit angiogenesis and also
disrupt already established angiogenic networks. The initial prom-
ising observations in mice, however, were not supported by clinical
trials with general or partially selective inhibitors of MMPs [222–224].
Several reasons were implicated in the failure of MMP inhibitors in
patients, including the sole targeting of only late stages of cancer
disease and the relative lack of MMP speciﬁcity of the inhibitors.
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levels of their cell origin, e.g. stromal vs. tumor, their cellular or
extracellular targets, e.g. endothelial cells vs. tumor cells vs. ECM, their
biochemistry, e.g. compensatory overexpression, alternative modes of
activation and processing of multiple substrates, may essentially pre-
determine the non-unilateral consequences of inhibition of MMP
functions. Thus, the abrogation of the inﬂux of MMP-9-delivering
macrophages in CCLR2-deﬁcient, K14-HPV/E2mice, genetically prone
to develop cervical cancer, was associated with a compensatory
inﬁltration of developing tumors with MMP-9-positive neutrophils
[23]. These ﬁndings suggest that if tumor-promoting, pro-angiogenic
macrophages are suppressed, then MMP-9 delivering neutrophils are
recruited to provide highly angiogenic, TIMP-free proMMP-9 and
elicit an alternative mechanism, supporting tumor angiogenesis and
cancer progression [23,48,143]. In addition, adaptive-evasive
responses by tumors leading to a resistance to anti-angiogenic
therapy involving growth factor/receptor inhibitors have been
recently demonstrated to include up-regulation of alternative pro-
angiogenic signaling pathways, recruitment of bone marrow-derived
vascular and hematopoietic progenitors and stabilization of newly
developed tumor blood vessels via pericyte coverage [185]. In view of
the above discussed properties and angiogenic functions of neutrophil
MMP-9, inhibition of the VEGF/VEGFR pathway driven by MMP-9-
producing macrophages may induce the compensatory FGF/FGFR
pathway driven by MMP-9-delivering inﬁltrating neutrophils and
thus speciﬁc targeting of inﬂammatory cell MMP-9 and not tumor-
derived MMP-9 (as was anticipated in the initial clinical trials) might
represent an alternative therapeutic approach.
13. Perspectives
The functional roles of MMPs in tumor neovascularization are
intrinsically associated with a speciﬁc aspect of aggressive cancer, i.e.
the nature of vessels utilized for metastatic tumor cell dissemination
[225,226]. Addressing this aspect poises additional questions perti-
nent to the regulation of tumor vascularization by MMPs, including:
(1) Do tumor cells intravasate into the newly formed vasculature of
the primary tumor, i.e. does the angiogenic vasculature serve as
conduits for tumor cell dissemination? If so, the pro-metastatic role of
MMPs in tumor cell dissemination would critically depend on the
overall outcome of positive and negative MMP contributions to tumor
angiogenesis and vasculogenesis. Although there is general agree-
ment that tumor neovascularization is linked to and required for
tumor metastasis, there is a relative paucity of experimental evidence
directly demonstrating intravasation of tumor cells into angiogenic
capillaries, rather than into pre-established blood vessels [45].
Moreover, recent evidence indicates that even if cancer dissemination
occurs through tumor-induced angiogenic vessels, it might be
efﬁcient only at the early stages of angiogenic network development,
i.e. before endothelial cell normalization [227]. It would be of
particular interest to analyze whether MMPs are involved in this
normalization of the vasculature. (2) If disseminating tumor cells,
however, intravasate into the pre-established vasculature (either
hematogenous or lymphatic), do MMPs facilitate cancer dissemina-
tion via those vessels co-opted by the tumor or surrounding the
tumor? If implemented, this scenario apparently would critically
depend on MMP-mediated proteolytic modiﬁcations of tumor ECM,
especially at the tumor border, assisting the escape, invasion,
directional migration towards and subsequent intravasation of
tumor cells into pre-existing blood vessels. This scenario would also
imply that MMP-assisted tumor dissemination might, paradoxically,
be independent of those functions of MMPs, which are directly related
to tumor neovascularization such as angiogenic switching, growth
factor release and recruitment of progenitor cells. These aspects of
MMP pleiotropic functionality remain experimentally unexplored,
awaiting further research for their resolution.References
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